However, single-agent therapy with the BCL2-specific inhibitor venetoclax (ABT-199, PubChem 254741640) had only a 12% complete response (CR) rate in relapsed/refractory DLBCL and 14% CR in follicular lymphoma in a phase I study [20]. This evidence concerns the gene BCL2 and follicular lymphoma.